Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
Huifang Huang,Kunhai Wu,Lufei Chen,Xiaomei Lin
DOI: https://doi.org/10.2147/IJGM.S346610
IF: 2.145
2021-12-18
International Journal of General Medicine
Abstract:Huifang Huang, 1 Kunhai Wu, 2 Lufei Chen, 2 Xiaomei Lin 1 1 Intensive Care Unit, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China; 2 Blood Transfusion Department, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China Correspondence: Kunhai Wu; Lufei Chen Tel +86 13906921205; +86 13705032570 Fax +86 591-87555474 Email ; Objective: We aimed to evaluate whether the systemic inflammatory response index (SIRI) and platelet lymphocyte ratio (PLR) are associated with ovarian malignancy and their diagnostic value. Design: This retrospective study compared SIRI, PLR, cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 199 (CA199), A carcinoma embryonic antigen (CEA) and alpha fetal protein (AFP) of the two groups in Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University from January 2018 to December 2020, divided into two groups based on pathological results, including 85 with ovarian malignancy who met the study criteria and 85 patients with benign ovarian tumors were randomly selected as control group. Results: 1) SIRI and PLR in benign ovarian tumor group were lower than those in ovarian malignancy group; 2) SIRI and PLR in ovarian malignant tumor low stage group were lower than those in the high stage group; 3) In ovarian malignancies, SIRI and PLR were positively associated with CA125 (the correlation coefficient r = 0.251, p = 0.021; r = 0.251, p = 0.020;) but showed no correlation with CA153. Conclusion: The study shows that SIRI and PLR are both convenient and associated with ovarian malignancy. SIRI and PLR can be used to help the differentiation of benign and malignant ovarian tumors and can also be used in the markers of ovarian malignant tumors roughly staging. Keywords: ovarian malignancy, SIRI, PLR Ovarian cancer is one of the most common tumors in worldwide. It can be divided into ovarian malignant tumors and ovarian benign tumors. Ovarian malignant tumor is the most fatal gynecologic malignancy, 1 and the onset is only second to cervical cancer and endometrial cancer. 2 Although ovarian cancer in early stage can be successfully treated, it is commonly detected at advanced stages with extensive local and systemic spread and poor survival. The 5-year survival rate of patients with ovarian malignant tumor stage I is 90%, while patients with stage IV is insufficient 11%. 3 Therefore, early diagnosis of ovarian malignant tumors may effectively reduce mortality. Diagnosis of ovarian malignant tumors is based on history, physical examination, tumor biomarker tests, imaging examination and histopathological examination. However, these inspections take much time and are expensive. The asymptomatic nature of ovarian cancer makes it difficult to detect in the early stages. 4 The study found that CA125 lacks specificity in the clinical diagnosis of ovarian cancer, 5 CA153 was first discovered in breast cancer epithelial cells. CA19-9 has good specificity for the diagnosis of gastrointestinal tumors, and has a synergistic effect on the diagnosis of ovarian cancer. 6,7 AFP is of great significance to the diagnosis and evaluation of ovarian cancer. 8 Up to 50% of patients with epithelial ovarian cancer have elevated CEA levels. 9 The tumor biomarker did not significantly changed in some early ovarian malignant tumor. Therefore, we need easier tests to screen for ovarian malignancies. Multiple lines of evidence suggest that ovarian cancer may be related to chronic inflammation. 10 SIRI and other indicators related to inflammation are closely related to the recurrence and overall survival of many malignant tumors. NLR, MLR, and PLR are good indicators to reflect systemic inflammation. 11 More and more studies have found that there is a significant correlation between malignant tumors and PLR. Some studies have confirmed that platelets play an important role in the growth, metastasis and angiogenesis of malignant tumors. 12 This paper focuses on the correlation of SIRI and PLR with ovarian tumors, in order to provide a reference index for the clinical screen of ovarian tumors. This was a retrospective study, including women who were admitted to Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University for surgical treatment from January 2018 to December 2020. SIRI is the ratio of neutrophil × monocyte/lymphocyte; PLR is the ratio of platelet to lymphocyte. Inclusion criteria included: a. new patients who were diagnosed -Abstract Truncated-
medicine, general & internal